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CFTR is involved in the regulation 
of glucagon secretion in human and 
rodent alpha cells
Anna Edlund1, Morten Gram Pedersen  2, Andreas Lindqvist3, Nils Wierup3, Malin Flodström-
Tullberg  4 & Lena Eliasson  1
Glucagon is the main counterregulatory hormone in the body. Still, the mechanism involved in the 
regulation of glucagon secretion from pancreatic alpha cells remains elusive. Dysregulated glucagon 
secretion is common in patients with Cystic Fibrosis (CF) that develop CF related diabetes (CFRD). 
CF is caused by a mutation in the Cl− channel Cystic fibrosis transmembrane conductance regulator 
(CFTR), but whether CFTR is present in human alpha cells and regulate glucagon secretion has not 
been investigated in detail. Here, both human and mouse alpha cells showed CFTR protein expression, 
whereas CFTR was absent in somatostatin secreting delta cells. CFTR-current activity induced by cAMP 
was measured in single alpha cells. Glucagon secretion at different glucose levels and in the presence of 
forskolin was increased by CFTR-inhibition in human islets, whereas depolarization-induced glucagon 
secretion was unaffected. CFTR is suggested to mainly regulate the membrane potential through an 
intrinsic alpha cell effect, as supported by a mathematical model of alpha cell electrophysiology. In 
conclusion, CFTR channels are present in alpha cells and act as important negative regulators of cAMP-
enhanced glucagon secretion through effects on alpha cell membrane potential. Our data support that 
loss-of-function mutations in CFTR contributes to dysregulated glucagon secretion in CFRD.
Glucagon is the main hyperglycemic hormone in the body and is released during fasting and extensive exercise. 
The hormone is released from pancreatic alpha cells, situated in the islet of Langerhans together with insulin 
secreting beta cells and somatostatin secreting delta cells. The islets of Langerhans are clusters of cells which are 
spread throughout the exocrine part of pancreas and constitute the endocrine part of the organ. Currently, we 
have not reached the full understanding of the cell physiology regulating glucagon secretion, and both intrinsic 
and paracrine regulation has been suggested to be involved1, 2. For example, it has been hypothesized that gluca-
gon is released as a result of an intermediate whole-cell KATP-conductance, i.e. only part of the KATP-channels 
are open, at low glucose concentration resulting in activation of voltage-dependent Na+ and Ca2+ channels3, 4. 
The resulting influx of Ca2+ initiates exocytosis of glucagon-containing granules. According to this hypothesis 
glucagon secretion is maximally inhibited at a glucose concentration of ~5–6 mM as a consequence of closure 
of the KATP-channel and inactivation of voltage-dependent Na+ channels5. However, the regulation of alpha cell 
electrical activity and secretion has also been suggested to involve store-operated channels6. A recent mathemat-
ical model of electrical activity in alpha cells suggests that glucagon secretion is most likely controlled by a com-
bination of the two mechanisms7. SGLT2 Na+-glucose co-transporters have also been suggested to be involved 
in stimulus-secretion coupling in alpha-cells8, 9. Paracrine inhibition of glucagon secretion involves zinc10 and 
GABA11 released by beta cells, and somatostatin released from delta cells12, 13.
Somatostatin is known to inhibit both insulin and glucagon secretion14, 15. Pancreatic delta cells secrete soma-
tostatin in response to increased glucose levels, and this has been suggested to involve the activation of calcium 
induced calcium release (CICR)16. Paracrine effects on somatostatin secretion involve stimulation by glucagon 
and insulin when alpha- and beta cells are active17–20.
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The cystic fibrosis transmembrane conductance regulator (CFTR) is a Cl− channel that belongs to the 
family of ABC-transporter proteins and is activated by cAMP21. In accordance with the function of many 
ABC-transporters, CFTR, aside from conducting Cl− ions through its channel pore, can also act as a regulator 
of other ion-channels and proteins22. Mutations in the gene encoding the CFTR channel impair the ion channel 
function and causes cystic fibrosis (CF), a disease that is characterized by malfunction in secretion by the epithe-
lium in a variety of organs, including the respiratory tract, exocrine pancreas, sweat glands and the intestine23. 
Today patients with CF live longer and many develop Cystic Fibrosis Related Diabetes (CFRD), which is associ-
ated with impaired insulin secretion24, 25. The reduced insulin secretion has been suggested to at least in part be 
due to destruction of the beta cells by the damaged exocrine cells24, 26. However, recent studies in patients and 
animal models have suggested a direct role of CFTR in the control of insulin secretion24, 27–30, and we and others 
have recently shown presence of CFTR in pancreatic beta cells and its direct involvement in the regulation of 
processes controlling insulin secretion31, 32.
Here, we have investigated if CFTR is present in alpha- and delta cells and involved in the intrinsic mecha-
nisms regulating hormone secretion in human and mouse alpha- and delta-cells. For this purpose, we have used 
patch-clamp registrations of current activation, hormone secretion assays, capacitance measurements as a meas-
ure of exocytosis, and mathematical modelling to interpret our findings.
Results
CFTR protein is expressed in human and mouse alpha cells. First, we used human pancreas sections 
to investigate the presence of CFTR in human islet alpha-and delta-cells using immunohistochemistry. We found 
that CFTR is expressed in human alpha cells but not in delta cells (Fig. 1A). We next moved on to investigate the 
CFTR localization in human alpha cells on the single cell level. The cells were stained for glucagon and CFTR 
and investigated using a confocal microscope (Fig. 1B). This enabled determination of subcellular localization of 
CFTR immunostaining, e.g. in the plasma membrane region compared to the cytosolic region (P1/P2). The CFTR 
Figure 1. CFTR is present in mouse and human alpha cells, but absent in delta cells. (A) Immunofluorescence 
of CFTR in sections of human pancreas. Immunostaining for CFTR (A.A), glucagon (A.B) and somatostatin 
(A.C), the overlay showing co-localization (A.D). Representative images from 3 donors and 20 islets from each 
donor that were investigated. (B) Confocal immunolocalization of CFTR (yellow) and glucagon (green) in fixed 
single pancreatic human alpha cell. (C) Mean intensity ratio (P1/P2) of CFTR antibody in the plasma membrane 
(P1) compartment compared to cytosolic compartment (P2) in human alpha cells (n = 30 cells from N = 3 
donors). (D) As in B, but image showing a single mouse alpha cells. (E) As in C, but the estimate was made in 
mouse alpha cells (n = 7 cells from N = 2 mice). Plasma membrane region was 0.5 μm. White scale bar indicates 
50 μm in A and 5 μm in B and D.
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signal was almost two-fold higher in the plasma membrane region compared to the cytosol in human alpha cells 
(Fig. 1C). Similar results were obtained in mouse alpha cells (Fig. 1D–E).
CFTR-inhibitors enhance glucose-regulated glucagon secretion. We were interested in deter-
mining if CFTR is involved in the regulation of glucagon secretion in human islets. Isolated islets from human 
cadaver donors were incubated at 2.8 mM glucose (Fig. 2A). Forskolin, known to increase intracellular cAMP, 
was used to activate CFTR, as well as other cAMP-dependent pathways in the alpha cell6, 33. Forskolin induced a 
2-fold increase in glucagon secretion that was further increased in the presence of the CFTR inhibitor, GlyH-101. 
Similar results were observed when glucagon secretion was measured from islets incubated at 6 mM (Fig. 2B) and 
16.7 mM (Fig. 2C) glucose. To address whether there are off target effects of GlyH-101 on alpha cells, mouse and 
human islets were treated with siRNA against CFTR and glucagon secretion was measured (Suppl. Fig. 1). These 
data confirmed that the effect of GlyH-101 on glucagon secretion is indeed via CFTR. 
We also measured release of somatostatin from the same islets. At all glucose concentrations (Fig. 2D–F) 
forskolin stimulated an increase in somatostatin secretion that was unaffected by inhibition of CFTR (Fig. 2D–F).
In mouse islets, glucagon secretion at 1 mM glucose was enhanced in presence of forskolin, this was further 
increased by ~30% in presence of GlyH-101 (Fig. 3A), in accordance with the results in human islets. However, 
at 16.7 mM glucose glucagon secretion remained virtually unchanged with or without CFTR-inhibition (Fig. 3B). 
Glucose-stimulated somatostatin secretion in mouse islets at 16.7 mM was significantly increased by forskolin and 
both GlyH-101 and CFTRinh-172 significantly reduced the amplifying effect of forskolin on glucose-stimulated 
somatostatin secretion (Fig. 3D).
Figure 2. Effects on glucagon- and somatostatin secretion after CFTR inhibition in human islets. (A) Glucagon 
secretion measured in human islets (N = 9) incubated for 1 h at 2.8 mM glucose (2.8G) in the presence or 
absence of 10 μM forskolin (Fsk) and 50 μM GlyH-101 (GlyH). (B) Same as in A, but measurements were 
performed at 6 mM glucose (6G) (N = 9). (C) Same as in A, but measurements were performed at 16.7 mM 
glucose (16.7G) (N = 9). (D–F) Same as A–C, but somatostatin secretion was measured (N = 11). *p < 0.05 
**p < 0.01, ***p < 0.001.
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CFTR current detected in human and mouse single alpha cells. To determine if human alpha cells 
have active CFTR currents we performed patch-clamp cell-attached single channel recordings. The voltage was 
held at −50 mV and continuous current activity was measured. It is not easy to detect CFTR single channel 
current in primary cells, but we managed to detect current opening of the size (~0.7 pA) and direction typical of 
CFTR34, suggesting the presence of CFTR in alpha cells (4A-B). The open probability (po) of the current increased 
with forskolin (n = 6 cells from 2 donors), and in three of the cells investigated GlyH-101 was added and found to 
decrease po to the level of control. We further performed whole cell current measurements in single mouse alpha 
cells. In these experiments a whole-cell current was initiated by the application of a voltage ramp from −100 mV 
to +100 mV (Fig. 4C–E). In the absence of forskolin the ramp protocol evoked a minimal current, while addition 
of forskolin evoked a significant increase in current. The cAMP-dependent increase in current was almost totally 
inhibited by the CFTRinh-172 (Fig. 4C,D). The current inhibited by CFTR-inhibitors (CFTR-dependent) con-
stituted 76 ± 9% (n = 5) of the forskolin-activated current at negative potentials (Fig. 4E). The CFTR-dependent 
conductance in mouse alpha cells was estimated to 61 ± 20 pS/pF at negative potentials (−100 mV to −50 mV) 
and the Cl− reversal potential was measured to ECl −61 ± 2 mV.
Depolarization-induced glucagon- and somatostatin-secretion is reduced by CFTR-inhibition 
in mouse but not in human islets. We have previously suggested that CFTR act together with the 
Ca2+-activated chloride channel Anoctamin 1 (ANO1) in the regulation of insulin secretion in pancreatic beta 
cells (Edlund et al.31), suggesting a role in exocytosis. We therefore investigated if inhibitors of CFTR (GlyH-101) 
and ANO1 (T16Ainh-AO1) have any effect on depolarization-induced glucagon secretion using a high concen-
tration of K+. Human islets were incubated for 15 minutes in presence of 1 mM glucose and 50 mM KCl (50 K+). 
Forskolin significantly enhanced secretion 3-fold, an increase that was unaffected by the CFTR-inhibitor and the 
inhibitor of ANO1 (Fig. 5A). It was ascertained that GlyH-101 did not have any effect in the absence of forsko-
lin (Fig. 5B). In rodent alpha cells the inhibitors of CFTR, GlyH-101 and CFTRinh-172, surprisingly reduced 
depolarization-induced secretion in presence of forskolin (Fig. 5C). Moreover, addition of the ANO1-inhibitor 
Figure 3. CFTR inhibition on glucagon and somatostatin secretion in mouse islets. (A) Glucagon secretion 
from mouse islets incubated for 1 h in 1 mM glucose (1G), 10 μM forskolin (Fsk) and/or 50 μM GlyH-101 
(GlyH) as indicated (N = 4). (B) As in A, but experiments where performed at 16.7 mM glucose (16.7G) and 
also in presence of 40 μM CFTRinh-172 (CFTRinh) as indicated (C) As in A but somatostatin secretion was 
measured (N = 4) (D) As in C, but experiments where performed in presence of 16.7 mM glucose (N = 9). 
*p < 0.05, **p < 0.01.
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into the incubation media reduced K+ -stimulated glucagon secretion to the same extent as GlyH-101 and there 
was no additive effect in the simultaneous presence of GlyH-101 and T16Ainh-AO1 (Fig. 5D), suggesting that 
CFTR and ANO1 at least partly regulate mouse alpha cells through effects on exocytosis as has been described in 
beta cells. This made us measure exocytosis in single mouse alpha cells as an increase in membrane capacitance 
(ΔCm). Experiments were performed using the standard whole-cell configuration of the patch-clamp technique 
and the intracellular solution was supplemented with cAMP. Alpha cells were pre-incubated in the absence (con-
trol) or presence of 10 μM CFTRinh-172 for ten minutes prior to capacitance measurements and exocytosis was 
evoked by a train of ten 500-ms depolarisations from −70 mV to 0 mV (Fig. 5E). In summary, the total exocytotic 
response evoked by the train (∑all, Fig. 5F) was significantly reduced in cells pre-incubated with CFTRinh-172 
compared to control alpha cells.
We measured somatostatin secretion from the same islets as used for glucagon secretion measurements in 
Fig. 5A,C,D to observe how depolarization-induced somatostatin secretion is affected by CFTR and ANO1 inhi-
bition. Depolarization- induced somatostatin secretion was enhanced by forskolin in both human and mice islets 
(Fig. 6A–C). In human islets (Fig. 6A), addition of any of the inhibitors of CFTR or ANO1 did not affect the 
response to forskolin significantly. However, in mouse islets (Fig. 6B,C), inhibition of either CFTR or ANO1 
reduced depolarization-induced somatostatin secretion. Moreover, there was no additive effect between the 
CFTR-inhibition and inhibition of the Ca2+ activated chloride channel (Fig. 6C).
Simulation of alpha cell electrical activity explains the role of CFTR in alpha cells. The secre-
tion experiments show that active CFTR channels inhibit glucagon secretion in the presence of forskolin and 
different concentrations of glucose. CFTR has no effects downstream of cell membrane depolarization in human 
alpha cells, and affect exocytosis positively in mouse alpha cells. This might contribute to the well-established 
cAMP-mediated effects downstream of Ca2+ influx33, 35. Together, these findings indicate that the main overall 
negative role of CFTR seen in the glucagon secretion experiments is due to effects on alpha cell electrical activity. 
To get theoretical insight into the feasibility of this hypothesis, we inserted a CFTR-dependent current based on 
our electrophysiological characterization into the recent alpha cell model by Watts and Sherman7. Our simulations 
Figure 4. Effects of CFTR inhibition on currents single human and mouse alpha cells. (A) Representative 
recordings showing the single-channel activity of CFTR in single human alpha cells using the cell-attached 
mode. Traces shown are in presence of 10 μM forskolin (Fsk) and the voltage was clamped at −50 mV. Dotted 
lines (over the whole traces) indicate the closed channel state and downward deflections correspond to channel 
openings. (B) Single-channel current amplitude (i; left) and open probability (po; right) in the absence (Ctrl, 
light grey) or presence of 10 μM Fsk (grey) and in the simultaneous presence of Fsk and 50 μM Gly-H-101 
(GlyH, black). (n = 6 cells from N = 2 donors). (C) Representative recordings showing whole-cell currents in 
single mouse alpha cells upon stimulation with voltage ramps from −100 mV to +100 mV in a single alpha cell 
performed in the absence (Ctrl, light grey) or presence of 10 μM forskolin (Fsk, grey) and in the simultaneous 
presence of forskolin and CFTRinh-172 (CFTRinh, black). Current ramps were applied before and every 
fourth minute after the application of forskolin until steady state was achieved. (D) Bar graph of the membrane 
conductance at negative voltages from −100 mV to −50 mV in alpha cell under the different conditions as in C 
(n = 5). (E) Calculated forskolin-activated and CFTR-dependent current from data in C. Currents shown are 
mean of n = 5 cells from 4 mice. *p < 0.05.
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showed that the effect of CFTR inhibition depends on the KATP conductance of the model cell (Fig. 7A–C). At low 
KATP conductance, gKATP = 0.200 nS, corresponding to 6 mM glucose3, CFTR inhibition leads to a slight increase 
in action potential firing frequency (Fig. 7A). With more KATP channels open (gKATP = 0.270 nS), corresponding 
to 1 mM glucose3 the result is similar, though the effect on the firing frequency is more pronounced (Fig. 7B). At 
slightly higher KATP conductance, gKATP = 0.300 nS, which is still within experimental variation observed at 1 mM 
glucose3, the cell is silent with CFTR operating, but activates once CFTR is inhibited (Fig. 7C). Thus, these simula-
tions suggest that CFTR negatively regulates alpha cell activity in two ways: (i) by reducing action potential firing, 
and (ii) by silencing some alpha cells that are active in the absence of the CFTR current.
Figure 5. Effect of CFTR inhibition on depolarization evoked glucagon secretion in human and mouse 
alpha-cells. (A) Glucagon secretion in human islets stimulated for 15 minutes by 50 mM K+ in the absence 
and presence of 10 μM forskolin (Fsk), 50 μM GlyH-101 (GlyH) and 50 μM TMinh-AO1 (AO1) as indicated 
(N = 4). (B) Glucagon secretion in human islets stimulated for 15 minutes by 50 mM K+ in the absence of 
forskolin and in the presence of 20 μM or 50 μM GlyH-101 (GlyH) as indicated (N = 3). (C) Glucagon secretion 
in mouse islets measured after 15 min incubation at 1 mM glucose (1G) in the presence of 50 mM KCl (K+) and 
10 μM forskolin (Fsk) and 40 μM CFTRinh-172 (CFTRinh) or 50 μM GlyH-101 (GlyH) as indicated (N = 4). 
(D) As in C, but the effect of the ANO1 inhibitor T16Ainh-AO1 (AO1) on Fsk enhanced and GlyH-inhibited 
glucagon secretion was investigated in mouse islets. (N = 4). (E) Representative traces of increases in membrane 
capacitance (ΔCm; bottom) in single mouse alpha cells when exocytosis was elicited by a train of ten 500 ms 
depolarizations from −70 mV to 0 mV (top). CFTR was activated by presence of 0.1 mM cAMP in the pipette 
solution under control conditions (Control; top) and in cells pre-incubated for 10 min with CFTRinh-172 
(CFTRinh; bottom) (F) Summary of the increase in membrane capacitance under control conditions (n = 5) 
and after 10 min preincubation with CFTRinh-172 (n = 7). Data is presented as the increase in membrane 
capacitance evoked by all 10 pulses of the train (∑all), the two first pulses (∑1–2) or the latter eight pulses (∑3–10). 
*p < 0.05, **p < 0.01.
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Figure 6. Effect of CFTR inhibition on depolarization evoked somatostatin secretion in human and mouse 
islets. (A) Somatostatin secretion in human islets measured after 15 min incubation at 1 mM glucose (1G) in the 
presence of 50 mM KCl (K+) and 10 μM forskolin (Fsk) and 50 μM GlyH-101 (GlyH) as indicated (N = 4). (B) 
Somatostatin secretion in mouse islets measured after 15 min incubation at 1 mM glucose (1G) in the presence 
of 50 mM KCl (K+) and 10 μM forskolin (Fsk) and 40 μM CFTRinh-172 (CFTRinh) or 50 μM GlyH-101 (GlyH) 
as indicated (N = 4). (C) As in B, but the effect of the ANO1 inhibitor TMinh-AO1 (AO1) on FSK enhanced and 
GlyH-inhibited glucagon secretion was investigated in mouse islets. (N = 4). *p < 0.05, **p < 0.01.
Figure 7. Simulation of electrical activity in alpha cells after introduction of CFTR. (A) Electrical activity was 
simulated using the model of Watts and Sherman7 with gKATP = 0.200 nS (=6 mM glucose3), gL = 0.200 nS 
and with gCFTR = 0.100 nS. Gray bar indicate CFTR inhibition. (B) As in A but gKATP = 0.270 nS (=1 mM 
glucose3) and gL = 0.150 nS35. (C) As in A but with gKATP = 0.300 nS (within experimental range at 1 mM 
glucose according to ref. 3).
www.nature.com/scientificreports/
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Discussion
We have in this study specifically investigated CFTR in human and mouse pancreatic alpha cells. Our data 
demonstrate the presence of CFTR in pancreatic alpha cells and that CFTR is involved in the regulation of 
cAMP-dependent glucagon secretion.
CFTR has previously been demonstrated to be expressed in rat alpha cells36, and the authors speculated that 
impaired CFTR function would lead to increased glucagon secretion, since CFTR would normally hyperpolarize 
the alpha cell and hence inhibit glucagon secretion. Indeed, we could demonstrate increased glucagon secretion 
after inhibition of CFTR in both human and rodent islet. The alpha cell is sensitive to small changes in depolar-
ization and the difference in membrane potential between glucose concentrations that is inhibitory (6 mM) and 
stimulatory (1 mM) on glucagon secretion is only ~10 mV3. A more negative membrane potential from which the 
action potentials are generated is associated with increased action potential amplitude (more voltage-dependent 
Na+ and Ca2+ channels are opened) until a level of hyperpolarization where action potential firing stops3. The 
bell-shaped pattern of how glucose, through the regulation of the KATP channel conductance, alternate between 
inhibition and stimulation of electrical activity and glucagon secretion has been demonstrated by using decreas-
ing concentrations of diazoxid3, 4. Here we used the recent alpha cell model of Watts and Sherman7 to investigate 
the impact of a CFTR-dependent current on electrical activity (Fig. 7), and in Fig. 8 we put forward a suggestion 
on how to interpret our data based on these simulations. The black curve shows the typical bell-shaped relation-
ship between the KATP conductance and glucagon secretion37, and in the graph illustrative ranges of KATP conduct-
ance representing 6 mM and 1 mM glucose are indicated. Addition of forskolin amplifies glucagon secretion due 
to effects on e.g. granule mobilization and priming33, 38, but increasing cAMP also activates CFTR. According to 
the model simulations of electrical activity, activation of CFTR changes the threshold for electrical activity (left-
shift) and lowers it slightly due to a reduction in action potential frequency (Fig. 7). The summed effect of cAMP 
on priming and activation of CFTR will result in the red curve. Secretion at 1 mM glucose is thus represented 
by the grey area under the black line. Addition of forskolin at this glucose concentration increases secretion by 
moving the curve up, though some cells with KATP conductance in the upper end of the interval become inactive 
because CFTR is now operating, and the cells that remains active will slow down action potential firing. The net 
effect will result in glucagon secretion as indicated by the hatched red area. Inhibition of CFTR will reactivate 
cells inactivated by CFTR, accelerating action potential firing again, and secretion, which is still amplified by the 
cAMP effects on priming and secretion, is as indicated by the blue area. At 6 mM glucose, a similar scenario is 
occurring with the difference that it is only the action potential frequency that matters, since alpha cells now have 
a KATP conductance so low that activation of CFTR will not inactivate any of the cells. Thus, our model simula-
tions support the hypothesis that CFTR is involved in controlling the membrane potential in pancreatic alpha 
cell, keeping the glucagon secretion at a balanced low level. This electrophysiological explanation applies to and 
corresponds to our human secretion data, while other mechanisms contribute to CFTR function in mouse alpha 
cells as discussed below. This interpretation would agree with CFRD patients having reduced ability to suppress 
glucagon secretion in combination with insufficient insulin secretion during an oral glucose tolerance test39, 40.
In beta cells, we have previously shown that CFTR functions as a regulator of ANO1 as a part of the machin-
ery controlling priming of granules prior to exocytosis and release of insulin31. Our current data indicates that 
CFTR in mouse alpha cells can have this function in addition to its role as an ion channel controlling the mem-
brane potential. In human islets, however, the main effects on glucagon secretion of CFTR-inhibition is through 
regulation of the membrane potential, since neither CFTR-inhibitors nor blockers of ANO1 had any effects on 
depolarization-induced secretion. Hence, our current and earlier31 data suggest that the function of CFTR in 
Figure 8. Model suggesting how CFTR affects glucagon secretion in pancreatic alpha cells. Glucose stimulated 
glucagon secretion results in the black curve, while the summed effect of cAMP on amplification pathways 
and activation of CFTR results in the red curve. Inhibition of CFTR in the continued presence of cAMP results 
in the blue curve. Glucagon secretion at 1mM glucose is represented by the grey area under the black curve. 
Activation of CFTR and cAMP amplifies glucagon secretion represented by the hatched red area under the red 
curve. Inhibition of CFTR results in an increased glucagon secretion (blue area under the blue curve) due to 
increased action potential frequency and activation of otherwise silent alpha cells. A similar pattern is observed 
at 6 mM glucose but the KATP conductance is so low that activation of CFTR does not silence any alpha cells.
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alpha- and beta-cells differs. CFTR acts mainly as an ion-channel in alpha cells influencing the membrane poten-
tial, and as a regulator in beta cells controlling exocytosis through ANO1.
In addition to the findings in alpha cells, we show that CFTR is not present in human delta cells. How can we 
then explain the measured effects by the CFTR inhibitors on somatostatin secretion? At low glucose, the effects of 
the inhibitors are absent (rodent; Fig. 3C; human; Fig. 2D). Glucagon secretion have been suggested to stimulate 
somatostatin secretion, thus, the small increase in somatostatin secretion at intermediate glucose in human islets 
(Fig. 2E) might be due to the increased glucagon secretion in presence of the inhibitors in combination with 
reduced paracrine effects from neighbouring beta cells (ref. 31 and Fig. 1A). In mice, at high glucose (Fig. 3D) 
and during depolarization-induced stimulation of somatostatin secretion (Fig. 6), the reduced response in pres-
ence of CFTR inhibitors are most likely due to paracrine effects from beta cells. Recently the peptide, Urocortin 
3 (Ucn3) was shown to be co-released with insulin and to stimulate somatostatin secretion20. CFTR-inhibition in 
beta cells reduce exocytosis31 and theoretically this should also lead to the reduced release of Unc3, thus resulting 
in less somatostatin secretion. This scenario is clear in the rodent islet, but in human islets somatostatin secretion 
was not at all affected by CFTR inhibition. If this is due to a combination of glucagon secretion being stimulated 
and beta cell exocytosis inhibited or if the paracrine regulation differs between the species needs to be further 
investigated. It might be anticipated that the difference in islet architecture41 will impact the paracrine regulation.
The enhanced glucagon secretion after CFTR-inhibition might also be due to paracrine effects from neigh-
bouring beta cells, since insulin inhibits glucagon secretion1. However, at glucose concentrations below 3 mM 
it is well established that glucagon secretion is stimulated whereas insulin secretion is inhibited. Moreover, the 
CFTR inhibitors had no effect on insulin release  at low concentrations of glucose (ref. 31 and Fig. 1A,E). Thus, it 
is unlikely that the increase in glucagon release in the presence of CFTR inhibitors at low glucose concentrations 
is explained by paracrine insulin signals from beta cells. At high glucose, there is a possibility that the increased 
glucagon secretion after CFTR inhibition is partly due to reduced inhibition by insulin. However, our ion channel 
current measurements together with immunostainings indicate that CFTR has a higher expression in alpha cells 
than in beta cells. Hence, the major contribution to the enhanced glucagon secretion after CFTR-inhibition is 
most likely through intrinsic CFTR within the alpha cells rather than through paracrine signalling from neigh-
bouring beta cells.
It is well established that the insulin response to an oral glucose tolerance test is delayed and reduced in CF 
regardless of normal or impaired glucose tolerance. Glucagon secretion is less well studied, but impaired glucagon 
secretion in CF has been reported42, 43. With decreasing glucose tolerance the ability to suppress glucagon secre-
tion is increasingly impaired39, 40. Moreover, glucagon stimulates, while insulin inhibits, hepatic glucose produc-
tion. CF patients have, regardless of the degree of glucose intolerance, increased hepatic glucose production44–46. 
We speculate that glucagon hypersecretion could contribute to and worsen glucose control in CF and CFRD. Our 
results might also have implications for type 2 diabetic patients. Studies of whether inhibition of CFTR channel 
activity through impaired regulation might be one of the contributing factors to the observed dysregulated gluca-
gon secretion and failure to suppress glucagon when blood glucose increases also in these patients are warranted.
In summary, our data demonstrates the presence of functional CFTR channels in pancreatic alpha cells, and 
suggests CFTR to be involved in the control of the alpha cell membrane potential (ultimately) regulating gluca-
gon secretion. Our data agree with the earlier suggestion that CFRD is associated with impaired suppression of 
glucagon secretion during a glucose load39, 40, and suggest that loss-of-function mutations of CFTR would impair 
glucagon secretion mainly through an intrinsic alpha cell mechanism.
Methods
Ethical statement. The use of isolated human islets from deceased donors was approved by the ethics com-
mittees in Malmö and Uppsala, Sweden. All Animal procedures were approved by the local ethical committee 
for use of laboratory animals in Malmö, Sweden. All experiments were performed in accordance with relevant 
guidelines and regulations.
Islet isolation and cell culture. Islets from 20 human donors (F/M 9/11, age 60.3 ± 2.2, BMI 25.2 ± 0.9 kg/
m2, HbA1c 5.7 ± 0.09, days in culture 4.2 ± 0.5) were provided by the Nordic Network for Clinical Islet 
Transplantation (Uppsala, Sweden). Human islets were hand-picked to ensure high purity. Female NMRI 
mice (Bolmholtgaard, Denmark) were sacrificed by cervical dislocation and islets isolated by Collagenase P 
(Boehringer Mannheim, Sweden) digestion as previously described31. For cell culture, islets were transferred to 
calcium-free isolation solution and dispersed into single cells and cultured in RPMI-1640 medium (SVA, Sweden) 
supplemented with 5 mM glucose (human) 10 mM glucose (mouse), 5% (vol/vol) fetal calf serum, 100 μg/ml 
streptomycin, 100 IU/ml penicillin and 2 mM L-Glutamine (Sigma-Aldrich).
Immunohisto- and cytochemistry. Staining of pancreatic section. The following primary antibodies 
were used: mouse anti-CFTR, code: MATG-1061, dilution 1:50 (RD-Biotech, France), rabbit anti-somatostatin, 
code: N-SOM, dilution 1:800 (InkStar, Stillwater, MN), guinea pig anti-glucagon, code: M8707, dilution 1:2500 
(Euro-Diagnostica, Sweden). Antibodies were diluted in PBS containing 0.25% BSA and 0.25% Triton X-100. 
Human pancreatic sections (5 μm) were incubated with primary antibodies overnight at 4 °C, followed by rinsing 
in PBS with 0.25% Triton X-100 for 2 × 10 minutes. Thereafter, secondary antibodies (Donkey anti-rat Texas Red, 
1:400 for CFTR, donkey anti-rabbit Cy2 1:400 for somatostatin and donkey anti-guinea pig AMCA, 1:100 for 
glucagon) were applied for one hour at room temperature. Sections were again rinsed in PBS with 0.25% Triton 
X-100 and mounted in PBS:glycerol (1:1).
Staining of single alpha cells. Human or mouse single cells were seeded on poly-L-lysin (Sigma Aldrich, Sweden) 
coated dishes and cultured overnight. Cells were fixed and stained as described elsewhere31. Mouse monoclonal 
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anti-CFTR (MATG-1061, RD-Biotech, France) and Guinea pig polyclonal anti-glucagon (EuroProxima, 
Netherlands) were used, and secondary antibodies specific for mouse conjugated to Cy3 and guinea pig conju-
gated to Cy5 (Jackson, UK). Unspecific binding of the secondary antibodies was excluded by parallel experiments 
in the absence of the primary antibodies. Immunofluorescence was detected with a confocal microscopy (META 
510, Zeiss, Germany) using the 525 nm and 633 nm lines for excitation. Mean intensity analysis was performed 
using Zen software (version 2009, Zeiss, Germany). The same laser setting was retained between experiments 
enabling comparison of experiments performed at different occasions. Localization of CFTR was analyzed as 
described elsewhere31. In short, the ratio between the mean fluorescent intensity in the plasma membrane region 
(P1) and the cytosolic region (P2) was estimated. The width of the plasma membrane region was decided to 
0.5 μm.
Patch-clamp recordings. EPC10 amplifier and 8.80 pulse software (HEKA, Germany) was used to evoke 
and record currents and changes in membrane capacitance on single islet cells. Mouse alpha cells were distin-
guished from beta cells by the electrophysiological properties of the Na+ channel inactivation47. Current and 
capacitance measurements were performed at RT and 32–33 °C, respectively.
Single channel currents measurements were performed using the cell-attached mode. In these experiments 
both the pipette and bath solutions contained: 140 mM NMDG-Cl, 2 mM CaCl2, 1 mM MgCl2, 10 mM Hepes, 
16.7 mM glucose and 10 mM Manitol (pH 7.4), supplemented with 10 μM forskolin and 25 μM GlyH-101 
(Calbiochem, USA) as indicated. During recording the currents were filtered at 3 kHz and digitized at 10 kHz. On 
playback, traces were filtered at 500 Hz and analysed using Heka software.
Whole-cell currents and changes in membrane capacitance were measured using the whole-cell configura-
tion. To inhibit K+-fluxes in the current measurements, the intracellular solution was free from K+-ions and 
the extracellular solution was supplemented with the K+-channel blocker TEACl. Extracellular solution con-
tained: 118 mM NaCl, 20 mM TEACl, 5.6 mM KCl, 2.6 mM CaCl2, 1.2 mM MgCl2, 5 mM HEPES, 3 mM L-glucose 
(current measurement)/5 mM L-glucose (capacitance measurement) pH 7.4 (NaOH), supplemented with 10 μM 
forskolin and/or 10 μM CFTRinh-172 (both from Sigma Aldrich, USA) and/or 25 μM GlyH-101 (Calbiochem, 
USA), as indicated. The intracellular solution contained: 125 mM CsOH, 125 mM Glutamate, 10 mM CsCl, 
10 mM NaCl, 1 mM MgCl2, 3 mM Mg-ATP, 5 mM HEPES (pH 7.15 with CsOH). For the current measurements 
4 mM EGTA was included to the intracellular solution and for capacitance measuremenst 0.05 mM EGTA and 
0.1 mM cAMP was added.
Hormone secretion measurements. Glucagon and somatostatin secretion was measured in static batch 
incubations described previously33. Briefly, batches with 12 islets (in quadruplicates) were pre-incubated in KRB 
supplemented with 1 mM glucose for 30 min followed by 1 h incubation at 1, 2.8, 6 or 16.7 mM glucose and in the 
presence of 50 mM KCl, 10 μM forskolin, 40 μM CFTRinh-172, 20 μM or 50 μM GlyH-101 (Calbiochem, USA) 
and 50 μM T16Ainh-AO1 (Calbiochem, USA) as indicated. When 50 mM KCl was added to the solution equimo-
lar NaCl was removed. Forskolin, CFTRinh-172, GlyH-101 and T16Ainh-AO1 were dissolved in DMSO to a final 
concentration of <0.1% DMSO in the experiment. Glucagon and somatostatin secretion was measured using 
radioimmunoassay kit (Millipore, MA, USA and Euro-Diagnostica, Malmö, Sweden, respectively).
Mathematical model. We used the recent mathematical model of electrical activity in pancreatic alpha 
cells by Watts and Sherman7. This model is based on electrophysiological characterizations of mouse alpha cells 
located in intact islets47, 48, and we based our simulations on the version of the model without store-operated cur-
rents operating (Fig. 1 in ref. 7). We inserted a CFTR current into the model. The CFTR current was represented 
as a passive current, ICFTR = gCFTR (V-VCl), where the conductance gCFTR = 0.100 nS and the Cl− reversal potential 
VCl = −60 mV were based on the experimental results presented here. The value for gCFTR was slightly lower than 
estimated from our experiments in order to produce robust electrical activity. This we attribute to the different 
experimental conditions, in particular the use of isolated alpha cells for the characterization of the CFTR current, 
in contrast to the use of intact islets for the parameters of the other currents in the model, and in secretion exper-
iments. All expressions and parameters are as in Watts and Sherman7, except the parameters for the leak current, 
which were set to VL = 0 mV, and gL = 0.150 nS or gL = 0.200 nS for 1 or 6 mM glucose, respectively. Simulations 
were performed using the code solver in the XPPAUT software. Computer code can be found in the supplemen-
tary material.
Statistical analysis. Data are presented as mean ± SEM of N number of individuals or independent exper-
iments or n number of cells. In the hormone secretion experiments, N number of human donors or experiments 
(islets from 3–4 mice were pooled for each secretion experiment) was used for the statistical analysis using 2-way 
ANOVA. All patch-clamp measurements and confocal immunostainings were analysed as n number of cells using 
Students t-test. p < 0.05 was considered statistically significant.
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